StockData
Monte Rosa Therapeutics, Inc. logo

Monte Rosa Therapeutics, Inc. (GLUE) stock

GLUENasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 7/3039% above fair value
$9.07+0.00 (0.00%)

Close on Nov 18, 2026Market cap $773.79MP/E –Yield –

Monte Rosa Therapeutics price to book ratio

The price-to-book ratio is market cap divided by shareholders' equity.

Monte Rosa Therapeutics's price to book ratio was 1.8× on Nov 11, 2026, against 4.1× a year earlier. Over the last 5 years it ranged from 0.8× to 5.4×, with a median of 1.5×.

Price to Book Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 20261.8×−2.1
2025Dec 31, 20253.9×+1.9
2024Dec 31, 20242.1×+0.5
2023Dec 29, 20231.5×+0.3
2022Dec 30, 20221.3×−1.3
2021Dec 31, 20212.6×–

More Monte Rosa Therapeutics figures

See a number that looks wrong?